Investigator Council

Misson

To support The GOG Foundation, Inc. in its quest to transform the standar of care in gynecologic oncology.

  • Business Development Subcommittee: To build deeper and broader relationships with pharmaceutical partners.
  • Early Phase Clinical Trial Subcommittee:  To foster, support, and increase capabilities of sites to perform early phase drug development including first in human, CAR-T, etc.
  • Site Engagement/Trial Challenges Subcommittee:  To help overcome start-up, regulatory, enrollment challenges, and improve communications between sites, sponsors and the GOG Foundation.
  • Patient Advocacy/Clinical Trial Equity Subcommittee: To advocate for our patients, especially those who are underrepresented and to ensure clinical trial enrollment that reflects the incidence in prevalence in the disease in question that is being studied.
  • Translational Research Subcommittee:  To develop new biomarkers and understand the scientific underpinnings of our investigational products as well as catalyze the development of novel agents.

Leadership

  • Kathleen Moore – University of Oklahoma, Stephenson Cancer Center
  • Tom Herzog – University of Cincinnati
  • R Wendel Naumann (Chair), Levine Cancer Inst, Atrium Health
  • Joyce Barlin, Women’s Cancer Care Associates, Albany, NY
  • Stephanie Blank, Icahn School of Medicine at Mount Sinai
  • Sharyn Lewin, Holy Name Medical Center
  • Michael McHale, University of California, San Diego: Moores Cancer Center
  • Emily Prendergast, Intermountain Healthcare
  • Mark Shahin, Abington Jefferson Hospital
  • Krishnansu Tewari, University of California, Irvine
  • Premal Thaker (Chair), Washington University School of Medicine
  • Rachel Grisham, Memorial Sloan Kettering Cancer Center
  • Gottfried E Konecny, University of California Los Angeles
  • Robert Morris, Wayne State University School of Medicine
  • Richard Penson, MGH / Harvard
  • Debra Richardson, Stephenson Cancer Center, University of Oklahoma Health Sciences Center
  • Noelle Cloven (Co-Chair, Texas Oncology Fort Worth
  • John Hays (Co-Chair), The Ohio State University James Cancer Center
  • Charles Anderson, Willamette Valley Cancer Institute
  • Michael Bookman, Kaiser Permanente Northern California
  • William Bradley, Medical College of Wisconsin
  • Linda Duska, University of Virginia
  • Melissa Geller, University of Minnesota
  • Cara Mathews, Women and Infants’ Hospital of Rhode Island
  • Jyoti Mayadev, University of California San Diego
  • Robert R Wenham,  Moffitt Cancer Center
  • Tashanna Myers (Chair), Baystate Medical Center
  • Victoria Bae-Jump, University of North Carolina at Chapel Hill
  • Destin Black, Trials365, LLC
  • Tara Castellano. LSU Health Sciences Center
  • Dana Chase, University of California LA
  • Sharad Ghamande, Augusta University (GRU)
  • Amanda Jackson, University of Cincinnati
  • Colleen McCormick,  Johns Hopkins University
  • Jessica Thomes Pepin, Minnesota Oncology – US oncology
  • Katherine Fuh (Co-Chair),  University of California, San Francisco
  • Anil K. Sood (Co-Chair),  MD Anderson Cancer Center
  • Sarah Adams, University of New Mexico Comprehensive Cancer Center
  • Doris Benbrook, Stephenson Cancer Center, University of Oklahoma Health Sciences Center
  • Casey Cosgrove, The Ohio State University Comprehensive Cancer Center
  • Oliver Cosgrove, Stanford University
  • Jae-Hoon Kim, Korean Gynecologic Oncology Group (KGOG)
  • Panagiotis Konstantinopoulos, Dana Farber Cancer Institute
  • Helen Mackay, Sunnybrook Odette Cancer Centre
  • Karen McLean, Roswell Park Comprehensive Cancer Center
  • Mary Mullen, Washington University School of Medicine
  • Andrew Nixon, Duke University
  • Fiona Simpkins, University of Pennsylvania
  • Oladapo Yeku, Massachusetts General Hospital
  • Dmitriy Zamarin, Icahn School of Medicine at Mt. Sinai